A drug used to treat angina may lengthen lifespan: Ranolazine-based therapy for life-span extension: Ranolazine (trade name: Ranexa) may increase insulin sensitivity, slow down cardiac aging, and increase lifespan, via up-regulation of BubR1 and others genes, 17/August/2018, 11.36 pm
Relax(in) your way to keep the cardiac diseases at bay: Relaxin-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Relaxin, a reproductive hormone, increases the expression of ERBB2/Her2 and promotes dedifferentiation of cardiomyocytes via down-regulation of its target gene, 17/August/2018, 11.19 pm
August 17, 2018
Unknown function of the known reproductive hormone Progesterone (P4) in Anti-metastasis therapy: Progesterone (P4), an endogenous steroid hormone, inhibits the expression of a number of enzymes in the glycolytic cycle and suppresses proliferation, migration, invasion, tumorigenesis, and metastasis, via upregulation of its target gene, 17/August/2018, 11.45 am
August 17, 2018What they say: Introduction:
A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July 2014 issue of the journal “EMBO”, by Prof Sinclair, North BJ, and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: A drug used to treat angina may lengthen lifespan: Ranolazine-based therapy for life-span extension: Ranolazine (trade name: Ranexa) may increase insulin sensitivity, slow down cardiac aging, and increase lifespan, via up-regulation of BubR1 and others genes
From research findings to Therapeutic Opportunity:
This study suggests, for the first time, that Ranolazine, by increasing the expression of their target gene, they may: (a) increase the expression of BuBR1; (b) decrease the expression of p70 S6 Kinase; and (c) regulate the expression of a number of longevity-promoting molecules (fig. 1).
Figure 1. Ranolazine may extend mammalian lifespan via up-regulation of BuBR1 and down-regulation of p70 S6 Kinase
Figure 2. Ranolazine functions as a longevity-promoting agent (fig 1).
Thereby, it may: (1) increase insulin sensitivity; (2) attenuate cognitive impairment; (3) delay diseases of aging; (4) slow down cardiac aging; (5) promote resistance to bone, immune and motor dysfunction; (6) promote tissue rejuvenation; and (7) prolong median lifespan. Thus, Ranolazine or its analogs, either alone or in combination with other drugs,“ may be used to extend the lifespan of an individual (fig.2).
[easy_payment currency=”USD”]
Details on the research findings:
Idea Proposed/Formulated (with experimental evidence) by:
Dr L Boominathan Ph.D.
Amount: $75
0#
Undisclosed mechanistic information: How Ranolazine increase the expression of BubR1 and extend mammalian life-span
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
# Research cooperation
References:
Web: http://genomediscovery.org or http://newbioideas.com
Citation: Boominathan, L., A drug used to treat angina may lengthen lifespan: Ranolazine-based therapy for life-span extension: Ranolazine (trade name: Ranexa) may increase insulin sensitivity, slow down cardiac aging, and increase lifespan, via up-regulation of BubR1 and others genes, 17/August/2018, 11.36 pm, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at admin@genomediscovery.org
